摘要
目的探讨血液透析治疗对血清中microRNA-92a的去除效果及其损伤内皮细胞功能的机制。方法收集西安高新医院长期透析治疗的慢性肾病患者,分别收集透析前、透析后6 h左右血清,测定其中miR-92a含量变化,同时测定BUN、Scr及hsCRP水平变化。培养的内皮细胞给予慢性肾脏病患者透析前后血清刺激,观察miR-92a及其靶基因eNOS表达变化。结果透析前后血清中miR-92a含量(1.48±0.24 vs 1.20±0.18,P=0.356)及hsCRP(7.6±2.4 vs 7.5±3.1,P=0.862)水平无显著差异。而透析治疗可显著降低血清中BUN(26.4±8.8 vs 8.3±2.3,P<0.01)、Scr(926.3±178.1 vs 312.3±141.2,P<0.01)水平。进一步体外细胞实验RT-PCR检测证实与健康人血清相比,慢性肾脏病患者透析前后血清均可促使培养的脐静脉内皮细胞miR-92a表达增加(P<0.01),RT-PCR及Western Blot检测证实其靶基因eNOS表达均显著降低(P<0.01),内皮细胞功能受损。结论血液透析治疗前后血清中miR-92a下降不明显,miR-92a可致内皮细胞eNOS表达减少,这可能是透析治疗虽然能维持肾脏功能但是无法避免其心血管并发症发生的部分原因。
Objective To explore the effect of hemodialysis therapy on removal of serum microRNA-92a and its mechanism on injury of vascular endothelial cells.Methods The serum samples of patients with chronic kidney diseases in XI’AN GaoXin Hospital treated with long-term hemodialysis were collected before and 6h after dialysis,and serum miR-92a level,BUN,Scr and hsCRP were measured.The cultured endothelial cells were stimulated with the serum samples from patients with chronic kidney diseases before and after dialysis,so as to observe the expression changes of miR-92a and its target gene eNOS.Results There was no significant difference in serum miR-92a level(1.48±0.24 vs 1.20±0.18,P=0.356)and hsCRP(7.6±2.4 vs 7.5±3.1,P=0.862)before and after hemodialysis.Serum BUN(26.4±8.8 vs 8.3±2.3,P<0.01)and Scr(926.3±178.1 vs 312.3±141.2,P<0.01)levels were decreased significantly by hemodialysis therapy.The further in vitro cell assay,RT-PCR,confirmed that compared with the normal healthy human serum,the serum from chronic kidney disease patients before and after dialysis could promote expression of miR-92a n in the cultured HUVEC(P<0.001).RT-PCR and Western Blot test demonstrated that the expression of its target gene eNOS was significantly reduced(P<0.001).Conclusions Serum miR-92a level does not obviously decrease after hemodialysis.miR-92a can reduce the expression of eNOS in endothelial cells,which may be part of the reason why dialysis can maintain renal function but cannot prevent against cardiovascular complications.
作者
王蕊
尚粉青
叶玉兰
惠玲玲
郭瑄
王慧
WANG Rui;SHANG Fen-qing;YE Yu-lan;HUI Ling-ling;GUO Xuan;WANG Hui(Department of Cardiology,Xi'an Gaoxin Hospital,Xi'an 710075,China)
出处
《临床肾脏病杂志》
2019年第4期236-239,260,共5页
Journal Of Clinical Nephrology
基金
国家自然科学基金青年基金项目(81800397)
陕西省卫生健康科研项目(2018D005)
